Pediatric functional constipation: Societies release new clinical care pathway

A new consensus clinical care pathway from two leading gastroenterology societies provides a standardized, stepwise approach to diagnosing and managing functional constipation in children, emphasizing clinical evaluation over testing and early use of laxatives to improve outcomes.

Published in Clinical Gastroenterology and Hepatology, the pathway was developed by AGA and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition, based on a literature review and consensus from a panel of 13 multidisciplinary experts, and aims to reduce practice variation while improving care across primary and specialty settings.

Functional constipation affects about 10% of children worldwide and is a common reason for referral, yet management varies widely. The expert panel required at least 70% agreement on recommendations, ultimately reaching full consensus across diagnostic and treatment domains.

Diagnosis centers on history, not testing

The pathway prioritizes history and physical examination, reserving diagnostic testing for patients with alarm features or treatment-refractory disease. The authors recommend using Rome IV criteria as guidance but note that clinicians can diagnose constipation based on clinical judgment even if criteria are not fully met.

Routine imaging is discouraged. Abdominal radiography shows limited diagnostic accuracy, with sensitivity ranging from 60% to 80% and specificity from 43% to 99% and should be used selectively when examination is not feasible or findings are discordant.

Similarly, colonic transit studies and anorectal manometry are recommended only in select scenarios, such as when the diagnosis is unclear or a motility disorder is suspected, and do not reliably predict treatment response.

Stepwise treatment approach

Treatment begins with diet, behavioral strategies, and pharmacologic therapy, escalating only when needed. Although evidence for increased fiber intake is limited, a healthy diet is recommended, along with structured toileting and caregiver education.

Medical therapy is organized into three phases: disimpaction, maintenance, and withdrawal. Polyethylene glycol is recommended as first-line therapy, with doses of 1 to 1.5 g/kg daily for three to five days for disimpaction and lower doses for maintenance.

Osmotic laxatives are the preferred initial maintenance therapy, with stimulant laxatives added if needed, but early use is encouraged. The pathway notes that polyethylene glycol is more effective than alternatives such as lactulose or milk of magnesia, although differences are modest.

Among newer agents, linaclotide showed benefit over placebo in pediatric trials and is approved for children older than six years, while lubiprostone did not outperform placebo in randomized trials.

For refractory cases, transanal irrigation achieved symptom improvement in 62% of patients in pooled analyses, and surgical options such as antegrade continence enemas are reserved for cases refractory to medical therapy.

Special populations and transition care

The pathway includes guidance for patients with neurodevelopmental disorders, who have higher rates of constipation and may present with atypical symptoms such as behavioral changes or poor appetite. Early referral to behavioral health specialists is recommended in these groups.

About one in four patients require care into adulthood, underscoring the importance of structured transition planning. The pathway outlines coordinated pediatric-to-adult care models and recommends starting transition discussions one to two years before transfer.

The authors concluded that standardizing evaluation and treatment can improve outcomes and reduce unnecessary testing. “Future efforts should focus on refining implementation strategies, evaluating real-world effectiveness, and addressing ongoing diagnostic and therapeutic debates,” they wrote.

The work was supported by AGA and NASPGHAN, with funding from an independent medical education grant from Ironwood Pharmaceuticals. Several authors reported relationships with industry, including consulting and speaking roles.

Expert insight

GI & Hepatology News asked Leonel Rodriguez, MD, MS, lead author of the clinical care pathway and Section Chief of Pediatric Gastroenterology & Hepatology at Yale School of Medicine, to discuss its implications for practice.

Why is now a good time for publication of this clinical care pathway? What gap(s) in knowledge or therapeutics does it seek to fill?

Dr. Rodriguez: Both the incidence and prevalence of functional constipation in children seem to be increasing over the last two decades (the former probably related to changes in dietary habits and behavioral disorders, and the latter probably due to lack of early detection and treatment and effective therapies leading to chronic symptoms). This makes constipation one — if not the most common — condition in the pediatric gastroenterologist’s office. For these reasons, both AGA and NASPGHAN teamed up to develop a clinical care pathway that addresses common gaps in the evaluation and management of functional constipation, from early detection to prompt and proper therapy, to transition to adult care, in a more universal and real-world approach.

In your opinion, what are the top clinical takeaways from this work?

Dr. Rodriguez: We wanted to provide pediatric providers with a framework to empower them to detect and treat children early in the course of the disorder, a detailed but practical guide for medical therapy that includes aggressive use of stimulant laxatives early in treatment and for long-term maintenance. We also aimed to embrace the concept that transition can be multidirectional, depending on the course of the symptoms, allowing primary care providers to resume the care of patients when treatment is successful.

As you and your coauthors assembled this document, was there a topic, or perhaps more than one, that caused more deliberation than usual?

Dr. Rodriguez: We reached full agreement in all topics discussed, but perhaps the one that required debate and discussion the most was the definition of constipation. We wanted to be inclusive and create a tool that helps pediatric providers care for all children.

Did any aspect of your clinical practice change because of helping to form this clinical care pathway?

Dr. Rodriguez: I worked very closely with non-physician clinical providers during the development of this pathway. I work with such providers in my day-to-day clinical practice but during this process I became more cognizant of the importance of their role in the care of children with functional constipation.

What additional research may be needed/what questions remain unanswered on this topic?

Dr. Rodriguez: There is still so much we do not understand about functional constipation in children, but emphasis should be placed on developing and test strategies to increase early detection and early therapeutic interventions that have the potential to improve the long-term outcomes.

Is there anything else you’d like to say about this work?

Dr. Rodriguez: This pathway illustrates the importance of collaboration between different disciplines to achieve a common goal: improve the health of our children.

Dr. Rodriguez disclosed that he is a speaker for Medtronic.